These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
433 related articles for article (PubMed ID: 28645240)
1. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus. Ahmad M; Ahmed OM; Schnepp B; Johnson PR Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240 [TBL] [Abstract][Full Text] [Related]
2. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1. Lin A; Balazs AB Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769 [TBL] [Abstract][Full Text] [Related]
3. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies. Ahmed Y; Tian M; Gao Y AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278 [TBL] [Abstract][Full Text] [Related]
4. [Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination]. Vzorov AN; Uryvaev LV Mol Biol (Mosk); 2017; 51(6):945-957. PubMed ID: 29271959 [TBL] [Abstract][Full Text] [Related]
9. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475 [TBL] [Abstract][Full Text] [Related]
10. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Brady JM; Baltimore D; Balazs AB Immunol Rev; 2017 Jan; 275(1):324-333. PubMed ID: 28133808 [TBL] [Abstract][Full Text] [Related]
11. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431 [TBL] [Abstract][Full Text] [Related]
12. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Williams WB; Zhang J; Jiang C; Nicely NI; Fera D; Luo K; Moody MA; Liao HX; Alam SM; Kepler TB; Ramesh A; Wiehe K; Holland JA; Bradley T; Vandergrift N; Saunders KO; Parks R; Foulger A; Xia SM; Bonsignori M; Montefiori DC; Louder M; Eaton A; Santra S; Scearce R; Sutherland L; Newman A; Bouton-Verville H; Bowman C; Bomze H; Gao F; Marshall DJ; Whitesides JF; Nie X; Kelsoe G; Reed SG; Fox CB; Clary K; Koutsoukos M; Franco D; Mascola JR; Harrison SC; Haynes BF; Verkoczy L Nat Commun; 2017 Nov; 8(1):1732. PubMed ID: 29170366 [TBL] [Abstract][Full Text] [Related]
13. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Verkoczy L; Alt FW; Tian M Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799 [TBL] [Abstract][Full Text] [Related]
14. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Landais E; Moore PL Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183 [TBL] [Abstract][Full Text] [Related]
15. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Moore PL; Williamson C; Morris L Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881 [TBL] [Abstract][Full Text] [Related]
16. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1). Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912 [TBL] [Abstract][Full Text] [Related]
17. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566 [TBL] [Abstract][Full Text] [Related]
19. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? Subbaraman H; Schanz M; Trkola A Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627 [TBL] [Abstract][Full Text] [Related]
20. Antibodies in HIV-1 vaccine development and therapy. Klein F; Mouquet H; Dosenovic P; Scheid JF; Scharf L; Nussenzweig MC Science; 2013 Sep; 341(6151):1199-204. PubMed ID: 24031012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]